Review paper
Intracrystalline Ozurdex® implant: iatrogenic intravitreal injection management
Abstract
The intravitreal dexamethasone implant Ozurdex® (Allergan, Inc, Irvine, Calif.) is indicated for the treatment of diabetic macular edema, venous occlusion of the retinal vessels, and noninfectious uveitis. In phakic patients, it is suggested that the injection should be done 4 mm posterior to the corneal limbus, directing the needle to the optic nerve, preferably in the inferotemporal quadrant. Although it is a rare event, inadvertent...
Paper Details
Title
Intracrystalline Ozurdex® implant: iatrogenic intravitreal injection management
Published Date
Aug 1, 2022
Volume
57
Issue
4
Pages
e121 - e122
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History